Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DPV 001

Drug Profile

DPV 001

Alternative Names: Autologous DRibble vaccine; Cancer vaccine DRibble; DPV-001; DRibble Vaccine

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UbiVac
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preclinical Bladder cancer; Breast cancer; Pancreatic cancer
  • No development reported Prostate cancer

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intralymphatic, Injection)
  • 08 Oct 2018 Preclinical trials in Bladder cancer (Combination therapy) in USA (Parenteral) (UbiVac pipeline, October 2018)
  • 08 Oct 2018 Preclinical trials in Breast cancer (Combination therapy) in USA (Parenteral) (UbiVac pipeline, October 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top